---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002702"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:45:17.016059+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics Q4 2024 net loss $34.5M; tau gene therapy VY1706 IND filing planned for 2026

## Summary
- Net loss $34.5M in Q4 2024 vs net income $56.4M in Q4 2023; full year net loss $65.0M vs income $132.3M.
- Collaboration revenue $6.3M in Q4 2024 vs $90.1M in Q4 2023; $80.0M full year vs $250.0M in 2023.
- Cash and marketable securities $332.4M as of Dec 31, 2024; runway extended into mid-2027 excluding milestones.
- Tau silencing gene therapy VY1706 reduced tau mRNA 50-73% in NHP study; IND filing anticipated in 2026.
- Anti-tau antibody VY7523 MAD study initiated; initial tau PET data in Alzheimer's patients expected H2 2026.

## SEC filing metadata
- accession: 0001558370-25-002702
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837025002702/0001558370-25-002702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837025002702/vygr-20250311x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002702
- JSON: https://secwatch.observer/filing/0001558370-25-002702.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.